Gilead wins reversal of US$2.54b hepatitis C drug patent verdict
Add BT as a preferred sourceBoston
A US federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record US$2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.
The verdict had been the largest ever in a US patent case but US District Judge Leonard Stark in Wilmington, Delaware, last Friday ruled that Merck's patent was invalid.
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
MSCI drops S-E Asian heavyweights Sembcorp, GoTo and Ayala Land from global benchmarks
